Therapeutic area intelligence for Diabetes Insipidus with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Companies: 1

Companies

Ferring Pharmaceuticals →

Assets

FDA →

Recent signals(1)

RegulatoryJuly 18, 2026

FDA Accepts Supplemental NDA for Desmopressin Acetate by Ferring Pharmaceuticals

The FDA has accepted a supplemental NDA for Desmopressin Acetate submitted by Ferring Pharmaceuticals.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Diabetes Insipidus →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.